A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: An analysis in 1135 patients with AML and 187 healthy controls

Experimental Hematology

Volumn 39, Issue 1, 2011, Pages 87-94

  Schnittger, Susanne ^a   Bacher, Ulrike ^b   Eder, Christiane ^a   Lohse, Peter ^c   Haferlach, Claudia ^a   Kern, Wolfgang ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AMINO ACID DUPLICATION; ARTICLE; CEPBA GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; EVENT FREE SURVIVAL; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TRANSACTIVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CCAAT-ENHANCER-BINDING PROTEINS; FEMALE; GENE DOSAGE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; REPETITIVE SEQUENCES, NUCLEIC ACID; TRANSCRIPTIONAL ACTIVATION; YOUNG ADULT;

EID: 78650214949     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.09.009     Document Type: Article

References (53)

1. Swansbury G.J., Lawler S.D., Alimena G., et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994, 73:1-7.
2. Bloomfield C.D., Shuma C., Regal L., et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997, 80:2191-2198.
3. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
4. Schoch C., Kern W., Schnittger S., Hiddemann W., Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004, 18:120-125.
5. Marcucci G., Mrozek K., Bloomfield C.D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005, 12:68-75.
6. Haferlach T., Bacher U., Kern W., Schnittger S., Haferlach C. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol 2007, 86:311-327.
7. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
8. Schlenk R.F., Dohner K. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 2009, 16:98-104.
9. Schnittger S., Schoch C., Dugas M., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
10. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106:3733-3739.
11. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
12. Yanada M., Matsuo K., Suzuki T., Kiyoi H., Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005, 19:1345-1349.
13. Pabst T., Mueller B.U., Zhang P., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270.
14. Preudhomme C., Sagot C., Boissel N., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100:2717-2723.
15. Gombart A.F., Hofmann W.K., Kawano S., et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002, 99:1332-1340.
16. Fröhling S., Schlenk R.F., Stolze I., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004, 22:624-633.
17. Lin L.I., Chen C.Y., Lin D.T., et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005, 11:1372-1379.
18. Ho P.A., Alonzo T.A., Gerbing R.B., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009, 113:6558-6566.
19. Swerdlow S., Campo E., Lee Harris N., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon, France.
20. Hollink I.H., van den Heuvel-Eibrink M.M., Zwaan C.M. CEBPA resembles Roman god Janus. Blood 2009, 113:6501-6502.
21. Tenen D.G., Hromas R., Licht J.D., Zhang D.E. Transcription factors, normal myeloid development, and leukemia. Blood 1997, 90:489-519.
22. Ward A.C., Loeb D.M., Soede-Bobok A.A., Touw I.P., Friedman A.D. Regulation of granulopoiesis by transcription factors and cytokine signals. Leukemia 2000, 14:973-990.
23. Friedman A.D., McKnight S.L. Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes Dev 1990, 4:1416-1426.
24. Lekstrom-Himes J., Xanthopoulos K.G. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem 1998, 273:28545-28548.
25. Antonson P., Xanthopoulos K.G. Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha). Biochem Biophys Res Commun 1995, 215:106-113.
26. Scott L.M., Civin C.I., Rorth P., Friedman A.D. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992, 80:1725-1735.
27. Radomska H.S., Huettner C.S., Zhang P., et al. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998, 18:4301-4314.
28. Wang X., Scott E., Sawyers C.L., Friedman A.D. C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999, 94:560-571.
29. Leroy H., Roumier C., Huyghe P., et al. CEBPA point mutations in hematological malignancies. Leukemia 2005, 19:329-334.
30. Tiesmeier J., Czwalinna A., Muller-Tidow C., et al. Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. Br J Haematol 2003, 123:413-419.
31. Pabst T., Mueller B.U. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res 2009, 15:5303-5307.
32. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
33. Mueller B.U., Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol 2006, 13:7-14.
34. Biggio V., Renneville A., Nibourel O., et al. Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 2008, 22:655-657.
35. Gilliland D.G. Hematologic malignancies. Curr Opin Hematol 2001, 8:189-191.
36. Resende C., Regalo G., Duraes C., Carneiro F., Machado J.C. Genetic changes of CEBPA in cancer: mutations or polymorphisms?. J Clin Oncol 2007, 25:2493-2494.
37. Fuchs O., Provaznikova D., Kocova M., et al. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis 2008, 40:401-405.
38. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628.
39. Wang H., Iakova P., Wilde M., et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 2001, 8:817-828.
40. Porse B.T., Pedersen T.A., Hasemann M.S., et al. The proline-histidine-rich CDK2/CDK4 interaction region of C/EBPalpha is dispensable for C/EBPalpha-mediated growth regulation in vivo. Mol Cell Biol 2006, 26:1028-1037.
41. Snaddon J., Smith M.L., Neat M., et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 2003, 37:72-78.
42. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
43. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
44. Kern W., Dannhauser-Riedl S., Ratei R., et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003, 88:646-653.
45. Schoch C., Schnittger S., Bursch S., et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002, 16:53-59.
46. Leecharendkeat A., Tocharoentanaphol C., Auewarakul C.U. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes. Int J Cancer 2008, 123:2321-2326.
47. Fuchs O. Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol (Praha) 2007, 53:97-108.
48. Wouters B.J., Louwers I., Valk P.J., Lowenberg B., Delwel R. A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 2007, 109:389-390.
49. Schnittger S., Kohl T.M., Leopold N., et al. D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. Genes Chromosomes Cancer 2006, 45:332-337.
50. Voso M.T., Fabiani E., D'Alo' F., et al. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol 2007, 18:1523-1528.
51. Bhatla D., Gerbing R.B., Alonzo T.A., et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia 2008, 22:265-272.
52. Monzo M., Brunet S., Urbano-Ispizua A., et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006, 107:4871-4879.
53. Muller P., Asher N., Heled M., et al. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res 2008, 32:919-929.